Premium
The association between P arkinson's disease and anti‐epilepsy drug carbamazepine: a case–control study using the UK G eneral P ractice R esearch D atabase
Author(s) -
Skow Áine,
Douglas Ian,
Smeeth Liam
Publication year - 2013
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.12100
Subject(s) - carbamazepine , odds ratio , confidence interval , medicine , epilepsy , population , case control study , disease , gastroenterology , psychiatry , environmental health
Aims To investigate whether the use of carbamazepine is associated with reduced risk of P arkinson's disease. Methods We conducted a population‐based, matched case–control study of patients randomly selected from the UK G eneral R esearch P ractice D atabase. We identified 8549 patients with Parkinson's disease using diagnosis criteria with a positive predictive value of 90%. These patients were compared with 42 160 control subjects matched for age, sex and general practice. Results Overall, 3.0% of cases (257 of 8549) had at least one recorded prescription for carbamazepine compared with 2.5% (1050 of 42 160) of controls. The crude odds ratio for the association between P arkinson's disease and carbamazepine was 1.22 (95% confidence interval 1.06–1.40), but this reduced to 0.93 (95% confidence interval 0.81–1.08, P = 0.34) after adjusting for annual consultation rate. Further adjustment for body mass index, smoking status, alcohol consumption or use of calcium channel blockers did not affect results. There was no evidence that risk decreased with higher doses or longer duration of carbamazepine use. Conclusions There was little to no evidence that use of carbamazepine is associated with reduced risk of P arkinson's disease. Although the study was underpowered, it does indicate that any effect of carbamazepine is likely to be small.